Author

M. Takeda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Cell Biology· 2 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2 Research Focus:development & morphogenesis· 2 Research Focus:cell signaling & trafficking· 1 Organism:Drosophila· 1

Frequent Co-Authors

H. Ohashi· 3 shared K. Kuramochi· 3 shared K. Watashi· 3 shared M. Muramatsu· 3 shared T. Suzuki· 3 shared T. Wakita· 3 shared W. Saso· 3 shared K. Hanada· 2 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

H. Ohashi

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

KRAS inhibition activates an actionable CD24 do-not-eat-me signal in pancreatic cancer

Y. Wei, M. Liu, E.-Y. Yen, J. Yao, Z. Xun, P. T. Nguyen, X. Wang, Z. Yang, A. Yousef, D. Pan, Y. Jin, C.-F. Li, M. S. Theardy, J. Park, Y. Cai, , H. Ying

This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.

bioRxiv · Sep 21, 2023Cancer Biology

Estimation of crossbridge-state during cardiomyocyte beating using second harmonic generation

T. M. Watanabe, H. Fujita, J. Kaneshiro, M. Takeda, K. Sasaki, R. Yamamoto, D. Umetsu, E. Kuranaga, S. Higo, T. Kondo, Y. Asano, Y. Sakata, S. Miyagawa

This paper develops a method to estimate crossbridge-state in cardiomyocytes using SHG polarization, showing its applicability in assessing myosin force generation and drug effects.

bioRxiv · Oct 13, 2022Biophysics

Establishment of Measles Virus Receptor-expressing Vero Cells Lacking Functional Poliovirus Receptors

K. Someya, Y. Okemoto-Nakamura, T. Kurata, D. Kanbayashi, N. Saito, M. Itamochi, N. Otsuki, K. Hanada, M. Takeda

The paper establishes PV-non-susceptible Vero cell lines for isolating measles and rubella viruses without PV replication risk.

bioRxiv · Jul 21, 2022Microbiology

Appropriate tension sensitivity of α-catenin ensures rounding morphogenesis of epithelial spheroids

R. Nishimura, K. Kato, M. Saida, Y. Kamei, M. Takeda, H. Miyoshi, Y. Yamagata, Y. Amano, S. Yonemura

This study shows that appropriate tension sensitivity of α-catenin is essential for epithelial cells to form round spheroids through multicellular rearrangement.

bioRxiv · Oct 27, 2021Cell Biology

Evaluation of the Efficacy and Safety of a Clinical Grade Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Patch: A Pre-Clinical Study

S. Miyagawa, T. Kawamura, E. Ito, M. Takeda, H. Iseoka, J. Yokoyama, A. Harada, N. Mochizuki-Oda, Y. Imanishi-Ochi, J. Li, M. Sasai, F. Kitaoka, M. Nomura, N. Amano, T. Takahashi, , Y. Sawa

This pre-clinical study evaluates the safety and efficacy of clinical-grade human iPSC-derived cardiomyocyte patches in treating heart failure, showing improved cardiac function and no adverse effects.

bioRxiv · Apr 7, 2021 · PreprintCell Biology

Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro

H. Ohashi, F. Wang, F. Stappenbeck, K. Tsuchimoto, C. Kobayashi, W. Saso, M. Kataoka, K. Kuramochi, M. Muramatsu, T. Suzuki, C. Sureau, M. Takeda, T. Wakita, F. Parhami, K. Watashi

This study identifies oxysterol derivatives with anti-SARS-CoV-2 activity, showing that Oxy210 and Oxy232 inhibit viral replication by disrupting double membrane vesicles.

bioRxiv · Jan 31, 2021Microbiology

Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes

S. Ikegame, T. Hashiguchi, C.-t. Hung, K. Dobrindt, K. Brennand, M. Takeda, B. Lee

The paper identifies hyperfusogenic measles virus F protein mutants associated with neuropathogenic phenotypes through a saturating mutagenesis screen.

bioRxiv · Dec 22, 2020Microbiology

Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro

K. Shionoya, M. Yamasaki, S. Iwanami, Y. Ito, S. Fukushi, H. Ohashi, W. Saso, T. Tanaka, S. Aoki, K. Kuramochi, S. Iwami, Y. Takahashi, T. Suzuki, M. Muramatsu, M. Takeda, , K. Watashi

This study identifies Mefloquine as a potent in vitro entry inhibitor of SARS-CoV-2 with higher antiviral activity than Hydroxychloroquine.

bioRxiv · Nov 19, 2020Microbiology

Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan

Y. Okemoto-Nakamura, K. Someya, T. Yamaji, K. Saito, M. Takeda, K. Hanada

The paper develops a poliovirus-nonsusceptible Vero cell line to support WHO's polio eradication efforts by reducing the risk of PV contamination in virus isolation.

bioRxiv · Aug 19, 2020Microbiology

The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects

M. Yamamoto, M. Kiso, Y. Sakai-Tagawa, K. Iwatsuki-Horimoto, M. Imai, M. Takeda, N. Kinoshita, N. Ohmagari, J. Gohda, K. Semba, Z. Matsuda, Y. Kawaguchi, Y. Kawaoka, J.-i. Inoue

This study shows nafamostat inhibits SARS-CoV-2 infection in vitro by blocking TMPRSS2-mediated fusion, with potency exceeding its blood concentration, suggesting it as a potential COVID-19 treatment.

bioRxiv · Apr 22, 2020 · PreprintMicrobiology

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

H. Ohashi, K. Watashi, W. Saso, K. Shionoya, S. Iwanami, T. Hirokawa, T. Shirai, S. Kanaya, Y. Ito, K. S. Kim, K. Nishioka, S. Ando, K. Ejima, Y. Koizumi, T. Tanaka, , T. Wakita

This study identifies a new multidrug combination treatment for COVID-19 using nelfinavir and cepharanthine, showing synergistic antiviral effects and improved disease control.

bioRxiv · Apr 14, 2020 · PreprintMicrobiology